Effects of menopausal hormone therapy on gut microbiota in postmenopausal women and the relationship with bone metabolismOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how menopausal hormone therapy (MHT) affects the gut microbiota of postmenopausal women and whether these microbial changes relate to bone metabolism. Fecal samples were analyzed using 16S ribosomal RNA gene sequencing and short-chain fatty acid (SCFA) analysis to characterize microbial composition. Serum bone metabolic markers were measured via chemiluminescent immunoassays, and Spearman correlation was used to test associations between specific bacterial genera and bone metabolism indexes.
Who was studied?
The study included a total of 31 postmenopausal women, some undergoing MHT and some not, whose fecal samples and blood serum were both collected and analyzed. The abstract does not provide further demographic details such as age range, geographic origin, or duration of MHT use.
What were the most important findings?
Postmenopausal women on MHT had lower serum levels of procollagen type I N propeptide (P1NP) and C-terminal telopeptide of type I collagen (CTX-1), both markers of bone turnover. Significant differences in both alpha diversity and beta diversity of gut microbial composition were observed between the MHT and non-MHT groups (P less than 0.05). Of 295 total microbial taxa identified, the abstract indicates specific taxa differed by group, though the full list of implicated genera is not given in the excerpt provided.
What are the greatest implications of this study?
The findings suggest that MHT's bone-protective effects, reflected in reduced bone-turnover markers, may occur alongside measurable shifts in gut microbial diversity and composition. This supports the broader concept that gut microbiota play a role in regulating bone metabolic processes in postmenopausal women. If confirmed, these associations could point toward gut microbiota as a potential mechanism or biomarker relevant to MHT's effects on bone health, though causality cannot be established from this abstract alone.